Federal
Register Notices > Rules - 2005
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
-
Implementation of the
Anabolic Steroid Control Act of 2004 (December 16, 2005
-
Proposed Rule 2005 - Controlled Substances and List I Chemical Registration and Reregistration Application Fees
(November 16, 2005)
-
Schedules of Controlled
Substances: Placement of Embutramide Into Schedule III;
Extension of Comment Period (August 29, 2005)
-
Clarification of Existing
Requirements Under the Controlled Substances Act for Prescribing
Schedule II Controlled Substances (August 26, 2005)
-
Reports by Registrants of
Theft or Significant Loss of Controlled Substances (August
12, 2005)
-
Schedules of Controlled
Substances: Placement of Embutramide Into Schedule III (July
29, 2005)
-
Schedules of Controlled
Substances: Placement of Pregabalin Into Schedule V (July
28, 2005)
-
Authority for
Practitioners To Dispense or Prescribe Approved Narcotic
Controlled Substances for Maintenance or Detoxification
Treatment (June 23, 2005)
-
Schedules
of Controlled Substances: Placement of Pregabalin into Schedule
V (May 13, 2005)
-
Preventing the Accumulation of Surplus
Controlled Substances at Long Term Care Facilities (May 13,
2005)
-
Definition and Registration of Reverse
Distributors (May 2, 2005)
-
Schedules
of Controlled Substances: Placement of Zopiclone Into Schedule IV
(April 4, 2005)
-
Electronic Orders for Controlled
Substances (April 1, 2005)
-
Proposed
Rule - Control of Sodium Permanganate as a List II Chemical
(March 1, 2005)
-
Proposed Rule - Schedules of Controlled Substances: Placement of Zopiclone Into Schedule IV
(February 14, 2005)
-
Chemical
Mixtures; Temporary Waiver of Import/Export Requirements
(February 4, 2005)
-
Solicitation
of Comments on Dispensing of Controlled Substances for the Treatment
of Pain (January 18, 2005)
-
Exemption of
Chemical Mixtures; Correction (January 4, 2005)
-
Recordkeeping
and Reporting Requirements for Drug Products Containing
Gamma-Hydroxybutyric Acid (GHB) (January 4, 2005)
|